Effectiveness of oral Itraconazole compared to Itraconazole Plus Isotretinoin for the Management of Superficial Dermatophytosis
DOI:
https://doi.org/10.66344/jpad.v36i2.3391Keywords:
dermatophytes, itraconazole, isotretinoinAbstract
Background Superficial dermatophytosis is a recurrent fungal infection affecting keratinized tissues, including the nails, skin, and hair. Recurrence and relapse of the disease remain major concerns despite advancements in antifungal treatment.
Objective To examine the safety and effectiveness of oral itraconazole with isotretinoin therapy versus itraconazole monotherapy in patients with superficial dermatophytosis.
Methods One hundred and twenty individuals with KOH-positive superficial dermatophytosis participated in a randomized clinical study. Group A received oral isotretinoin (20 mg once daily) along with oral itraconazole (100 mg twice daily) for eight weeks, whereas Group B received oral itraconazole (100 mg twice daily) alone. A 0-3 scale was used to assess the clinical severity of erythema, scaling, and pruritus. Liver function tests and lipid profiles were monitored at baseline and at 4-week intervals.
Results After eight weeks treatments both groups showed considerable improvement in erythema, scaling, and pruritus (P<.001). Mean erythema scores decreased from 2.98±0.13 to 0.20±0.52 in Group A and from 2.92±0.28 to 0.25±0.43 in Group B, representing improvements of 93.3% and 91.4%, respectively. No statistically significant intergroup differences were observed. The side effects were minimal and self-limiting.
Conclusion Although the combination of itraconazole and isotretinoin was well tolerated and safe, the outcomes were not statistically superior to those of itraconazole monotherapy. However, in severe or recurrent cases, isotretinoin may serve as a useful adjuvant by improving fungal clearance and increasing keratinocyte turnover.
References
1. Bitew A. Dermatophytosis: prevalence of dermatophytes and non-dermatophyte fungi from patients attending Arsho Advanced Medical Laboratory, Addis Ababa, Ethiopia. Dermatol Res Pract. 2018;2018:8164757. doi:10.1155/2018/8164757.
2. Sana S, Ahmed A, Nazir L, Shehzad U, Aftab MN, Ullah N, et al. Distribution, molecular characterization, and treatment options for dermatophyte and non-dermatophyte fungi isolated from human and animal samples: an integrated computational and experimental approach. Allergol Immunopathol (Madr). 2026;54(1):196-211.
3. Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6. doi:10.1186/s12895-018-0073-1.
4. Brigida S, Elizabeth AA, Soujania G, Poornima RP. A comparative study of safety and efficacy of oral terbinafine and itraconazole in patients of tinea corporis/tinea cruris infection: a randomized open label parallel group study. Biomed Pharmacol J. 2021;14(3):1543-9.
5. Verma KK, Senthilnathan G, Bhatia S, Xess I, Gupta V, Dwivedi SN, et al. Oral isotretinoin combined with oral terbinafine versus oral terbinafine alone to treat recurrent dermatophytosis: an open-label randomised clinical trial. Indian Dermatol Online J. 2021;12(6):820-5.
6. Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin: a prospective, randomized comparative study. Indian J Pharmacol. 2019;51(2):116-9.
7. Verma SB, Panda S, Nenoff P, Singal A, Rudramurthy SM, Uhrlass S, et al. The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options. Indian J Dermatol Venereol Leprol. 2021;87(4):468-82.
8. Tuknayat A, Bhalla M, Kaur A, Garg S. Familial dermatophytosis in India: a study of the possible contributing risk factors. J Clin Aesthet Dermatol. 2020;13(2):58-60.
9. Singh SK, Subba N, Tilak R. Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: a randomized controlled parallel group open labeled trial with clinico-mycological correlation. Indian J Dermatol. 2020;65(4):284-9.
10. Alhamdi DK, Alhamdi KI. Efficacy and safety of adding low-dose isotretinoin to itraconazole in the treatment of chronic recurrent dermatophytosis among a sample of Iraqi patients: an open-labelled therapeutic clinical comparative study. Indian J Dermatol. 2022;67(5):624.
11. Srivastava A, Kothiwala SK. Isotretinoin may affect pharmacokinetics of itraconazole in the skin: is it rational to combine both for the treatment of dermatophytosis? Indian J Dermatol Venereol Leprol. 2017;83(1):68.
12. Naseemullah, Khan AR, Aslam K, Obaid SM. Efficacy of itraconazole vs itraconazole plus isotretinoin in treatment of chronic tinea. Pak J Med Health Sci. 2021;15(10):3316-9.
doi:10.53350/pjmhs2115103316.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Journal of Pakistan Association of Dermatologists
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
